Q3 EPS Estimates for USANA Health Sciences Cut by Sidoti

USANA Health Sciences, Inc. (NYSE:USNA) – Stock analysts at Sidoti reduced their Q3 2026 earnings estimates for USANA Health Sciences in a research report issued on Wednesday, February 11th. Sidoti analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $0.49 for the quarter, down from their previous forecast of $0.54. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.52 EPS, FY2026 earnings at $1.84 EPS, Q1 2027 earnings at $0.64 EPS, Q2 2027 earnings at $0.65 EPS and FY2027 earnings at $2.77 EPS.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, February 17th. The company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19. The firm had revenue of $226.20 million for the quarter, compared to the consensus estimate of $225.96 million. USANA Health Sciences had a return on equity of 6.97% and a net margin of 1.86%.

A number of other analysts also recently weighed in on the stock. Zacks Research downgraded shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 7th. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. One research analyst has rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, USANA Health Sciences has a consensus rating of “Sell” and an average price target of $36.00.

USANA Health Sciences Trading Down 1.4%

Shares of USANA Health Sciences stock opened at $20.61 on Monday. USANA Health Sciences has a 12 month low of $18.48 and a 12 month high of $38.32. The firm has a market capitalization of $376.75 million, a P/E ratio of 23.42, a P/E/G ratio of 0.95 and a beta of 0.67. The business has a fifty day simple moving average of $20.72 and a two-hundred day simple moving average of $23.64.

Institutional Investors Weigh In On USANA Health Sciences

A number of institutional investors have recently made changes to their positions in USNA. Russell Investments Group Ltd. raised its holdings in USANA Health Sciences by 4.6% in the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock worth $244,000 after acquiring an additional 542 shares during the last quarter. ExodusPoint Capital Management LP increased its holdings in shares of USANA Health Sciences by 58.4% in the 4th quarter. ExodusPoint Capital Management LP now owns 28,625 shares of the company’s stock worth $562,000 after purchasing an additional 10,552 shares in the last quarter. Barclays PLC raised its stake in shares of USANA Health Sciences by 57.9% in the fourth quarter. Barclays PLC now owns 49,271 shares of the company’s stock worth $967,000 after purchasing an additional 18,068 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of USANA Health Sciences during the fourth quarter valued at $11,485,000. Finally, First Trust Advisors LP bought a new position in shares of USANA Health Sciences during the fourth quarter valued at $246,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.